Questions Concerning the Clinical Translation of Cell-Based Interventions under an Innovation Pathway

Authors

  • Jeremy Sugarman

    1. Harvey M. Meyerhoff Professor of Bioethics and Medicine at the Berman Institute of Bioethics, Department of Medicine, and Department of Health Policy and Management of the Johns Hopkins University in Baltimore, Maryland.
    Search for more papers by this author

Abstract

Stem cell-based innovation is one pathway to clinical translation that stands in contrast to clinical research and medical treatment. After reviewing recently issued guidelines for responsible innovation, this article examines the potential benefits and harms of using this pathway as well as practical barriers and conceptual concerns regarding it.

Ancillary